Multicentre clinical trial on amoxicillin/sulbactam for treatment of acute bacterial infections

Objective To evaluate the clinical efficacy and safty and adverse drug reaction of amoxicillin/sulbactam for acute bacterial infections. Methods A randomized controlled multicentre clinical trial on efficacy and safety of domestic amoxicillin/sulbactan in 1.5 g every 12 hours (light), 3.0 g every 12 hours (middle) and 3.0 g every 8 hours (serious) compared with amoxicillin/clavulanate in 1.2g every 12 hours (light), 2.4 g every 12 hours (middle) and 2.4 g every 8 hours (serious) for treatment of acute bacterial infections was conducted. Results The results showed that the curerates and efficacy rates in the test group were 80.88% and 95.58%, while the cure rates and efficacy rates in the control group were 75.36% and 94.20%, and the bacterial clean rate was 95.24%. The difference between the two groups was no statistically significant.There no serious adverse drug reactions of amoxicillin/ sulbactam in the clinical trial. Conclusion It suggested that amoxicillin/sulbactam is an effective and safe drug or treatment acute bacterial infections.